Moreover, miR-28 and miR-138 can target immune checkpoints and revert exhausted phenotypes, with miR-28 specifically resulting in interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF-α) secretion in the tumor microenvironment [94]. The gene discussed is IL2; the disease is neoplasm.